Editor’s pick: Firefly Bio

editor’s-pick:-firefly-bio

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Firefly Bio seeks to improve on antibody–drug conjugates and proteolysis-targeting chimeras by combining them as degrader–antibody conjugates.

References

Author information

Authors and Affiliations

  1. Ann Arbor, MI, USA

    Ken Garber

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garber, K. Editor’s pick: Firefly Bio. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02923-2

Download citation

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41587-025-02923-2